产品
编 号：F445301
分子式：C12H13ClN2O3
分子量：268.7
分子式：C12H13ClN2O3
分子量：268.7
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 74226-22-5
产品详情
生物活性：
Dazoxiben is a potent and orally active thromboxane (TX) synthase inhibitor.
体内研究：
Dazoxiben (intraperitoneal administration; 100 μg/kg)produces a marked prolongation of the tail bleeding time with 96.8 ± 10.8 secs.
体外研究：
Dazoxiben inhibits TXB2 production in clotting human whole blood with an IC50 of 0.3 μM and causes parallel enhancement of PGE2 greater than PGF2 alpha greater than 6-keto-PGF1 alpha production.Dazoxiben inhibits TXB2 production in rat kidney glomeruli with an IC50 of 1.60 μM) than in rat whole blood (IC50= 0.32μM), and is not associated with changes in PGE2, PGF2 alpha and 6-keto-PGF1 alpha production.
Dazoxiben is a potent and orally active thromboxane (TX) synthase inhibitor.
体内研究：
Dazoxiben (intraperitoneal administration; 100 μg/kg)produces a marked prolongation of the tail bleeding time with 96.8 ± 10.8 secs.
体外研究：
Dazoxiben inhibits TXB2 production in clotting human whole blood with an IC50 of 0.3 μM and causes parallel enhancement of PGE2 greater than PGF2 alpha greater than 6-keto-PGF1 alpha production.Dazoxiben inhibits TXB2 production in rat kidney glomeruli with an IC50 of 1.60 μM) than in rat whole blood (IC50= 0.32μM), and is not associated with changes in PGE2, PGF2 alpha and 6-keto-PGF1 alpha production.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备